Iran Approves WhartoCell, an Off-the-Shelf Allogeneic Umbilical Cord Stem Cell Therapy for Osteoarthritis
核心洞察
Iran has approved WhartoCell (搜索), an allogeneic mesenchymal stem cell therapy derived from Wharton's jelly of neonatal umbilical cord, for treating osteoarthritis (搜索).
The therapy is designed to reduce inflammation, support cartilage regeneration, and improve joint function without requiring HLA matching between donor and recipient.
Developed by Royan Institute under GMP standards, WhartoCell (搜索) is positioned as an off-the-shelf treatment to improve patient access to regenerative medicine.
Iran has taken a significant step in regenerative medicine with the approval of WhartoCell (搜索), an allogeneic stem cell therapy developed by researchers at Royan Institute for the treatment of osteoarthritis (搜索). The approval, reported on June 28, 2026, marks another milestone in the expansion of domestically developed regenerative medicine technologies in the country.
According to Mehdi Lotfipanah, Director of Public Relations and International Affairs at Royan Institute, the therapy is designed to reduce inflammation, support cartilage regeneration, and improve joint function in patients with osteoarthritis (搜索). "The introduction of innovative cell-based therapies requires a scientific and evidence-based approach to ensure their appropriate integration into clinical practice," Lotfipanah said.
Technical Profile and Mechanism of Action
WhartoCell (搜索) is derived from Wharton's jelly of the neonatal umbilical cord, a rich source of mesenchymal stem cells. These cells possess anti-inflammatory and immunomodulatory properties while supporting tissue repair and regeneration. A distinguishing feature of the product is that it does not require genetic matching, or HLA matching, between donor and recipient. This characteristic allows physicians to administer the treatment without lengthy preparation procedures, positioning WhartoCell as an off-the-shelf therapy expected to improve patient access to advanced regenerative treatments.
Manufacturing and Quality Standards
Royan Institute has emphasized that WhartoCell (搜索) is manufactured under Good Manufacturing Practice (GMP) standards, with quality and safety monitored throughout the production process. This adherence to internationally recognized manufacturing standards is intended to ensure consistent product quality and patient safety.
Broader Clinical Potential
Although WhartoCell (搜索) was initially approved for osteoarthritis (搜索), researchers at Royan Institute suggest the technology may have broader applications in regenerative medicine. Potential future indications include cartilage repair, tendon and ligament injuries, bone fracture healing, avascular necrosis, and the management of inflammatory joint disorders.
Strategic Significance
Lotfipanah noted that the product represents an important achievement in developing indigenous biotechnology, reducing dependence on imported therapeutic products while expanding access for healthcare providers across the country. He added that greater awareness among physicians and healthcare providers would facilitate broader adoption of regenerative medicine technologies.
Royan Institute plans to increase scientific communication around WhartoCell (搜索) through specialized workshops, educational programs for physicians and patients, and scientific meetings, including activities tied to the upcoming 27th International Royan Congress. The institute, one of Iran's leading centers for stem cell research and regenerative medicine, has developed several advanced cell-based therapeutic technologies over the past two decades as part of the country's growing biotechnology sector.